Market Intel: Precision Diagnostics And Focal Treatments Offer Personalized Approach To Prostate Cancer
The combined market for prostate cancer diagnostics and minimally invasive treatments is set to increase from $900m to $1.46bn in the next five years. But conservative treatment, or watchful waiting, is popular, limiting growth of newer, focal treatments.
You may also be interested in...
Artificial intelligence (AI) and machine learning took center stage at this year’s Radiological Society of North America meeting in Chicago, and the pervasiveness of AI tech in new product launches was further emphasized at the RSNA’s expanded AI Showcase exhibit.
With the opening of a new UK & Ireland headquarters last month, Intuitive Surgical is aiming to strengthen its grip on the the market as it faces increasing competition in the robotic surgery space. CEO Gary Guthart sat down with Medtech Insight at its new Oxfordshire, UK HQ to discuss expansion and innovation plans.
The company unveiled its new modular robotic surgery system for minimally invasive surgery at a special event in Hartford, CT. Medtronic expects the new system to earn a CE mark by early 2021 and FDA approval by the end of 2021.